Semin Thromb Hemost 2017; 43(07): 672-681
DOI: 10.1055/s-0037-1602666
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Thromboprophylaxis in Cancer Patients Undergoing Surgery

Kay T. Htun
1   Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
,
Agnes Y. Y. Lee
2   Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
3   Thrombosis Program, Vancouver Coastal Health, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
08 June 2017 (online)

Abstract

Venous thromboembolism (VTE) is a common, complex, and costly complication in cancer patients undergoing surgery. VTE risk varies with types of cancer surgery as well as patient-, cancer-, and treatment-associated factors. Current VTE preventive measures with pharmacological, mechanical, and combination of both are shown to be effective. Clinical questions remain and more research is needed, focusing on the role of thromboprophylaxis for minimally invasive surgery and major cancer surgery other than abdominal/pelvic surgery, as well as optimal duration of thromboprophylaxis in high-risk patients. Routine individual VTE risk assessment and better adherence to thromboprophylaxis guidelines may offer improved outcomes in cancer patients undergoing surgery. A summary of currently available evidence and consensus guidelines on the primary prevention of VTE in cancer patients undergoing various types of surgery is presented here.

 
  • References

  • 1 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160 (06) 809-815
  • 2 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
  • 3 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
  • 4 Khorana AA, Dalal MR, Lin J, Connolly GC. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res 2013; 5: 101-108
  • 5 Trujillo-Santos J, Nieto JA, Tiberio G. , et al; RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100 (03) 435-439
  • 6 Prandoni P, Lensing AW, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
  • 7 Lee AY, Levine MN, Baker RI. , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
  • 8 Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009; 7 (05) 760-765
  • 9 Geerts WH, Heit JA, Clagett GP. , et al. Prevention of venous thromboembolism. Chest 2001; 119 (1, Suppl): 132S-175S
  • 10 Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999; 84 (05) 437-445
  • 11 Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost 1991; 17 (Suppl. 03) 304-312
  • 12 Rogers Jr SO, Kilaru RK, Hosokawa P, Henderson WG, Zinner MJ, Khuri SF. Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg 2007; 204 (06) 1211-1221
  • 13 Gould MK, Garcia DA, Wren SM. , et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e227S-e277S
  • 14 Agnelli G, Bolis G, Capussotti L. , et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006; 243 (01) 89-95
  • 15 Sweetland S, Green J, Liu B. , et al; Million Women Study collaborators. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ 2009; 339: b4583
  • 16 Geerts WH, Bergqvist D, Pineo GF. , et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S
  • 17 Iversen LH, Thorlacius-Ussing O. Relationship of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer. Thromb Haemost 2002; 87 (03) 402-408
  • 18 Becattini C, Rondelli F, Vedovati MC. , et al. Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer. Haematologica 2015; 100 (01) e35-e38
  • 19 Sandadi S, Lee S, Walter A. , et al. Incidence of venous thromboembolism after minimally invasive surgery in patients with newly diagnosed endometrial cancer. Obstet Gynecol 2012; 120 (05) 1077-1083
  • 20 Kumar S, Al-Wahab Z, Sarangi S. , et al. Risk of postoperative venous thromboembolism after minimally invasive surgery for endometrial and cervical cancer is low: a multi-institutional study. Gynecol Oncol 2013; 130 (01) 207-212
  • 21 Walker JL, Piedmonte MR, Spirtos NM. , et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009; 27 (32) 5331-5336
  • 22 Heinzer H, Hammerer P, Graefen M, Huland H. Thromboembolic complication rate after radical retropubic prostatectomy. Impact of routine ultrasonography for the detection of pelvic lymphoceles and hematomas. Eur Urol 1998; 33 (01) 86-90
  • 23 Donat R, Mancey-Jones B. Incidence of thromboembolism after transurethral resection of the prostate (TURP)--a study on TED stocking prophylaxis and literature review. Scand J Urol Nephrol 2002; 36 (02) 119-123
  • 24 Scarpa RM, Carrieri G, Gussoni G. , et al; @RISTOS Study Group. Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. Eur Urol 2007; 51 (01) 130-135 , discussion 136
  • 25 Alberts BD, Woldu SL, Weinberg AC, Danzig MR, Korets R, Badani KK. Venous thromboembolism after major urologic oncology surgery: a focus on the incidence and timing of thromboembolic events after 27,455 operations. Urology 2014; 84 (04) 799-806
  • 26 Streiff MB, Ye X, Kickler TS. , et al. A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors. J Neurooncol 2015; 124 (02) 299-305
  • 27 Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000; 89 (03) 640-646
  • 28 Liwnicz BH, Wu SZ, Tew Jr JM. The relationship between the capillary structure and hemorrhage in gliomas. J Neurosurg 1987; 66 (04) 536-541
  • 29 Glass B, Abbott KH. Subarachnoid hemorrhage consequent to intracranial tumors; review of literature and report of seven cases. AMA Arch Neurol Psychiatry 1955; 73 (04) 369-379
  • 30 Scott M. Spontaneous intracerebral hematoma caused by cerebral neoplasms. Report of eight verified cases. J Neurosurg 1975; 42 (03) 338-342
  • 31 Wakai S, Yamakawa K, Manaka S, Takakura K. Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance. Neurosurgery 1982; 10 (04) 437-444
  • 32 Little JR, Dial B, Bélanger G, Carpenter S. Brain hemorrhage from intracranial tumor. Stroke 1979; 10 (03) 283-288
  • 33 Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8 (08) 610-622
  • 34 Kim WY, Lee HY. Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors. FEBS J 2009; 276 (17) 4653-4664
  • 35 Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 1994; 12 (06) 1266-1271
  • 36 Andtbacka RH, Babiera G, Singletary SE. , et al. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 2006; 243 (01) 96-101
  • 37 Agzarian J, Hanna WC, Schneider L. , et al. Postdischarge venous thromboembolic complications following pulmonary oncologic resection: An underdetected problem. J Thorac Cardiovasc Surg 2016; 151 (04) 992-999
  • 38 Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost 1989; 62 (04) 1046-1049
  • 39 Marassi A, Balzano G, Mari G. , et al. Prevention of postoperative deep vein thrombosis in cancer patients. A randomized trial with low molecular weight heparin (CY 216). Int Surg 1993; 78 (02) 166-170
  • 40 Bergqvist D, Flordal PA, Friberg B. , et al. Thromboprophylaxis with a low molecular weight heparin (Tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial. Vasa 1996; 25 (02) 156-160
  • 41 Mismetti P, Laporte S, Darmon JY, Buchmüller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88 (07) 913-930
  • 42 Bergqvist D, Burmark US, Flordal PA. , et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995; 82 (04) 496-501
  • 43 Cohen AT, Spiro TE, Büller HR. , et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011; 31 (04) 407-416
  • 44 ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84 (08) 1099-1103
  • 45 McLeod RS, Geerts WH, Sniderman KW. , et al; Canadian Colorectal Surgery DVT Prophylaxis Trial investigators. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian Colorectal DVT Prophylaxis Trial: a randomized, double-blind trial. Ann Surg 2001; 233 (03) 438-444
  • 46 Akl EA, Kahale L, Sperati F. , et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database Syst Rev 2014; 6 (06) CD009447
  • 47 Simonneau G, Laporte S, Mismetti P. , et al; FX140 Study Investigators. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost 2006; 4 (08) 1693-1700
  • 48 Kakkar AK, Agnelli G, Fisher W. , et al; SAVE-ABDO Investigators. Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. Ann Surg 2014; 259 (06) 1073-1079
  • 49 Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. ; PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92 (10) 1212-1220
  • 50 Vedovati MC, Becattini C, Rondelli F. , et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg 2014; 259 (04) 665-669
  • 51 Einstein MH, Pritts EA, Hartenbach EM. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecol Oncol 2007; 105 (03) 813-819
  • 52 Koch MO, Jr JS. Low molecular weight heparin and radical prostatectomy: a prospective analysis of safety and side effects. Prostate Cancer Prostatic Dis 1997; 1 (02) 101-104
  • 53 Nurmohamed MT, van Riel AM, Henkens CM. , et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996; 75 (02) 233-238
  • 54 Agnelli G, Piovella F, Buoncristiani P. , et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998; 339 (02) 80-85
  • 55 Macdonald RL, Amidei C, Baron J. , et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol 2003; 59 (05) 363-372 , discussion 372–374
  • 56 Salmaggi A, Simonetti G, Trevisan E. , et al. Perioperative thromboprophylaxis in patients with craniotomy for brain tumours: a systematic review. J Neurooncol 2013; 113 (02) 293-303
  • 57 Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med 2000; 160 (15) 2327-2332
  • 58 Dickinson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998; 43 (05) 1074-1081
  • 59 Mosley JG. Low-dose heparin in breast-cancer surgery. Lancet 1978; 1 (8056): 161
  • 60 Steele RJ, Richmond JD, Lee D, Chetty U, Davies GC. The effect of low-dose subcutaneous heparin on wound haemorrhage, a controlled study of mastectomy patients. Br J Clin Pract 1983; 37 (03) 95-98
  • 61 Lee RE, Ho KN, Karran SJ, Taylor I. Haemorrhagic effects of sodium heparin and calcium heparin prophylaxis in patients undergoing mastectomy. J R Coll Surg Edinb 1989; 34 (03) 149-151
  • 62 Friis E, Hørby J, Sørensen LT. , et al. Thromboembolic prophylaxis as a risk factor for postoperative complications after breast cancer surgery. World J Surg 2004; 28 (06) 540-543
  • 63 Cameron IC, Azmy IA. Thromboprophylaxis in patients undergoing surgery for breast cancer. Breast 2001; 10 (06) 535-537
  • 64 Christensen TD, Vad H, Pedersen S. , et al. Venous thromboembolism in patients undergoing operations for lung cancer: a systematic review. Ann Thorac Surg 2014; 97 (02) 394-400
  • 65 Allan A, Williams JT, Bolton JP, Le Quesne LP. The use of graduated compression stockings in the prevention of postoperative deep vein thrombosis. Br J Surg 1983; 70 (03) 172-174
  • 66 Turpie AG, Bauer KA, Caprini JA, Comp PC, Gent M, Muntz JE. ; Apollo Investigators. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost 2007; 5 (09) 1854-1861
  • 67 Bergqvist D, Agnelli G, Cohen AT. , et al; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346 (13) 975-980
  • 68 Rasmussen MS, Jorgensen LN, Wille-Jørgensen P. , et al; FAME Investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006; 4 (11) 2384-2390
  • 69 Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P. ; CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010; 8 (06) 1223-1229
  • 70 Fagarasanu A, Alotaibi GS, Hrimiuc R, Lee AY, Wu C. Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 2016; 23 (05) 1422-1430
  • 71 Birkmeyer NJ, Share D, Baser O. , et al; Michigan Bariatric Surgery Collaborative. Preoperative placement of inferior vena cava filters and outcomes after gastric bypass surgery. Ann Surg 2010; 252 (02) 313-318
  • 72 Girard TD, Philbrick JT, Fritz Angle J, Becker DM. Prophylactic vena cava filters for trauma patients: a systematic review of the literature. Thromb Res 2003; 112 (5-6): 261-267
  • 73 Mission JF, Kerlan Jr RK, Tan JH, Fang MC. Rates and predictors of plans for inferior vena cava filter retrieval in hospitalized patients. J Gen Intern Med 2010; 25 (04) 321-325
  • 74 Ko SH, Reynolds BR, Nicholas DH. , et al. Institutional protocol improves retrievable inferior vena cava filter recovery rate. Surgery 2009; 146 (04) 809-814 , discussion 814–816
  • 75 Lyman GH, Bohlke K, Khorana AA. , et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update 2014. J Clin Oncol 2015; 33 (06) 654-656
  • 76 Kearon C, Akl EA, Comerota AJ. , et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-e494S
  • 77 Mandalà M, Falanga A, Roila F. ; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl. 06) vi85-vi92